nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2015 | Image of the Month

In vivo visualization of prostate-specific membrane antigen in glioblastoma

verfasst von: Johannes Schwenck, Ghazaleh Tabatabai, Marco Skardelly, Gerhald Reischl, Rudi Beschorner, Bernd Pichler, Christian la Fougère

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

The expansion of nutrient vessels is an important factor in the growth of glioblastomas (GBM), which is one of the most vascularized tumours [1]. Therefore, new treatment concepts that include tumour vasculature targets are currently under investigation. Prostate-specific membrane antigen (PSMA) is overexpressed in the tumour vasculature of GBM, which therefore might be considered as a potential endothelial target for treatment with PSMA-based agents [2, 3]. However, according to the limited data so far available, PSMA expression in brain tumours varies with glioma grade [4]. …

Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–46. doi:10.1038/nrc1627.PubMedCrossRef

Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135:1486–9. doi:10.5858/arpa.2010-0740-OA.PubMedCrossRef

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182–91. doi:10.1158/1078-0432.CCR-13-0231.PubMedCentralPubMedCrossRef

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14:26. doi:10.1186/1475-2867-14-26.PubMedCentralPubMedCrossRef

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.PubMedCentralPubMedCrossRef

Titel: In vivo visualization of prostate-specific membrane antigen in glioblastoma
verfasst von: Johannes Schwenck
Ghazaleh Tabatabai
Marco Skardelly
Gerhald Reischl
Rudi Beschorner
Bernd Pichler
Christian la Fougère
Publikationsdatum: 01.01.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2921-5

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

In vivo visualization of prostate-specific membrane antigen in glioblastoma

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects

Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?

177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study

The difference between medicine and magic is that magicians know what they are doing

Test–retest reliability of 11C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain

Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery